A method of treating multiple sclerosis and degenerations of the nervous system

 

(57) Abstract:

The invention relates to medicine, namely to neurology. The patient is prescribed a daily intake of drugs that enhance mitochondrial oxidation in therapeutic doses. Place the patient in the treatment chamber. Spend compression to achieve excess pressure 0,03 - 0,1 ATA. After 10 to 20 minutes conclude the session by decompression. Daily repeated exposure to 4 - 10 sessions. The choice of parameters of treatment and number of sessions conducted individually depending on the severity and nature of the disease under control of the dynamics of neurological status, capnogram and/or KHS, a second course of treatment 2 times a year, and when the deterioration and more under the control of GENDER, immune status, evoked potentials and EEG. In the acute period of autoimmune inflammation of the method is combined with hormones, cytotoxic agents and immunomodulators in less than, the dose of, under the control of the immune status. The method can reduce the content of products of lipid peroxidation in plasma and to increase the body's natural defence. 1 C.p. f-crystals, 1 Il.

The invention relates to medicine, namely to neurology.

the, Yedinaya this disease with great hereditary neurodegenerations. In recent years, there are assumptions about the proximity of the PC to degenerative diseases, which are based on inherited or acquired defect of mitochondrial oxidation - energy cells. When PC had been a violation of microcirculation in the surrounding area of autoimmune inflammation of the area, defining continuous chronic autoimmune process.

The feature of multiple sclerosis and most neurodegenerative is a congenital or acquired defect in the antioxidant defense of the organism, mainly superoxide dismutase (SOD), the enzyme that protects the body from superoxide oxygen that leads to the development of "oxidative stress" associated with progressive degenerative diseases. The combination of pathological changes, when developing PC, and degenerations of the nervous system makes it impossible for spontaneous healing and patient leads to early disability and death. There is currently no effective treatment for degenerative diseases of the brain including the PC.

The use of hyperbaric oxygenation (HBO) in multiple sclerosis is how to cause activation of processes of lipid peroxidation (LPO), associated with degeneration of cell membranes. In our clinic for over 10 years in the treatment of PC and degenerations of the nervous system was used hyperbaric therapy at 1.2 ATA developed modifications [2,3].

The application of this method in the treatment of PC and neurodegenerative was accompanied by a separate regression of neurological symptoms only during the first and second sessions, and at the end of the course of 4-5 sessions were always observed activation of the FLOOR, despite the stabilization of the condition of most patients after treatment.

Closest to the claimed method is a Method of treatment of vascular diseases of the brain" [1] . However, this method of treatment for multiple sclerosis and degenerative diseases of the nervous system, accompanied by a defect in the antioxidant system of the body, can lead to activation of the FLOOR, which reduces the clinical effect of the method.

The aim of the proposed method is to increase the clinical effect of hypobaric hypoxic stimulation with PC and degenerations of the nervous system.

The proposed method is based on the use of safe therapeutic effects aimed at normalization of tissue respiration and peroxidation processes in multiple sclerosis and the money is. is therefore to improve the effectiveness of the positive impact of minimum excess pressure in the chamber is combined with drugs that increase the reserves of mitochondrial oxidation - ubiquinone and bioflavnoids (Pycnogenol®) or succinic acid.

The invention consists in obtaining a new quality when using the minimum excess pressure in the chamber, reducing the circulation and transport of drugs, ensuring the transfer of electrons in the respiratory chain of mitochondria. A combination of hypobaric hypoxic stimulation and drugs that increase the reserves of mitochondrial oxidation, observed increased energy and increase the body's natural defenses of the body.

The patient is prescribed a daily intake of drugs that increase the transport of electrons in the mitochondria, and bioflavnoidy in therapeutic doses, it is placed in the treatment chamber, and then purging the chamber with oxygen conducting compression air or oxygen at a rate of 0.01 MPa/min until reaching excessive pressure 0,03-0,1 MPa, then after 10-20 minutes conclude the session by decompression, daily repeated exposure within 1 or 2 weeks (from 4 to session), under coy carried out 2 times a year, and when the deterioration and more under the control of GENDER, immune status, evoked potentials, EEG, magnetoresonance tomography.

In the acute stage of autoimmune inflammation of the proposed method is combined with hormones or drugs (immunosuppressants) smaller than customary doses under the control of the patient, neurological and immune status, magnetic resonance imaging of the brain.

The main mechanism of action of the proposed method is the restoration of microcirculation and tissue respiration in the field of pathological lesions of autoimmune inflammation and immune organs. After each session on the proposed methodology, there is a strong increase of CO2breath and blood and disposal O2with the normalization of external respiration, viscosity and rheology of the blood, which indicates an increase of energy metabolism in the body.

A persistent decrease in peroxidation products in plasma after treatment by the present method may indicate a decrease in the intensity of degenerative processes in the body. The result is a regression of neurological symptoms and enhance the natural protection of the suppressor function of T-lymphocytes, increased levels of natural killer cells. The proposed method is not accompanied by the phenomenon of addiction - when repeat courses there is no damping effect of hypobaric hypoxic stimulation in contrast to HBO.

The use of the proposed method significantly reduces the toxic effect of hormones and drugs, increases their therapeutic effect at a lower dose and reduces the phenomenon of cancellation.

Clinical trials of the proposed method of treatment of patients with PC and degenerations of the nervous system was conducted in the neurology departments of 1 clinical hospital since September 1996 in the treatment of 36 patients with multiple sclerosis, 20 of which had previously been treated in the clinic with the use of hyperbaric therapy in previously established methods, 3 patients with Lou Gehrig's disease, 3 patients with the disease Charcot-Marie, 2 patients with motonishi myopathy, 3 patients with torsion dystonia, 4 patients with dementia type, 5 patients with Parkinson's disease, 2 patients with the gepatolentikuliarnaya degeneration.

The combined use bioflavonoid and hypobaric hypoxic stimulation by the developed technique was accompanied by a significant increase clinical effect of treatment in the hyperbaric chamber and especially medical aftereffect.

Monitor patients for 1.5 years with repeat courses of treatment by the present method have revealed increasing the duration of the effect of a course of treatment and marked regression of neurological symptoms. The patient works.

Comparative research on the effectiveness of the method in combination with Pycnogenol ® - plant water-soluble antioxidant (bioflavnoids) and ubiquinone - carrier electrons in the respiratory chain of mitochondria.

In Fig.1 shows the dynamics of neurological symptoms in points and lipid peroxidation (malondialdehyde in mmol/l) in the treatment of bolii with Pycnogenol®, 3) Pycnogenol ® and 4) control group.

When using the hypobaric hypoxic stimulation (patent N 2102958) separate regression of neurological symptoms was observed during the first sessions in the hyperbaric chamber, after 5 sessions at 1.1 ATA in most patients there was an increase of LPO products in the blood plasma. Combined use of Pycnogenol and Barataria was accompanied by a qualitatively new effect - each session of hypobaric hypoxic stimulation was accompanied by regression of neurological symptoms and observed significant decrease of LPO products in plasma after 5 sessions at 1.1 ATA.

A similar effect was obtained with the combined use Pycnogenol and ubiquinone, the use of which in the treatment of patients previously treated with only periodical hypobaric hypoxic stimulation and Pycnogenol®, caused regression of previously stable neurological symptoms. Using the proposed method of treatment has allowed to achieve significant therapeutic effect in patients with progressive for PC, treated in our clinic earlier.

Example. Sick T-C. 1959 R. was observed in the clinic since 1994 about the spinal form of multiple sclerosis, secondary-having a progressive course. Disabled of the first group from 1996 Received 2-3 alas after each course, there has been a slow progression of symptoms between treatments. The disease was aggravated 2-3 times per year with increasing ataxia and paresis in the right extremities. In December 1997, he received Pycnogenol ® in combination with periodical hypobaric hypoxic stimulation. After conducting in April 1998, of course hyperbaria of 6 sessions at 1.1 ATA in combination with Pycnogenol ® and ubiquinone in the claimed method in a patient for the first time after sessions hyperbaria observed regression of the number of previously resistant neurological symptoms of nystagmus, trunk ataxia, reduced paresis in the right limb, the disappearance of clonus feet and knees, the appearance of abdominal reflexes, significantly improved the General state of sleep. The patient goes and does the housework. There was an increased CO2breath, slowing down and deepening breathing, reduced FLOOR in blood plasma. Were observed normalization of viscosity and rheology of blood. Positive dynamics of immunological indicators: - increase in T-suppressor and E-killers while increasing the overall number of lymphocytes.

When the previously used methodology (3) the positive dynamics of neurological symptoms was observed in 70% of cases. After the course was observed a strong activation of the FLOOR, Noi system a state of chronic fatigue.

In contrast to the previously accepted practices when using the proposed method, the positive dynamics of disease symptoms was observed in virtually all patients, which is more efficient than previously used methods, which accounted for 70%. After treatment by the present method were observed normalization of the General condition, mood and sleep, longer delay and prolonged remissions.

Some of the increase in costs for the combined use of drugs pays off a large clinical effect, the reduction in bed-days, lengthening remissions and saving of expensive drugs used in the treatment of patients with multiple sclerosis and degenerations of the nervous system, generally disabled young age. Early use of the method when treating this group of patients is accompanied by a prolonged stabilization of the condition and improve their quality of life, sick for a long time remain employable. The inventive method of treatment is used in neurology and internal medicine departments of hospitals, clinics, rehabilitation centers.

Literature

1. Kazantseva, N. In., Gusev, E. I., Makarova L. D. treatment of vascular diseases the Ministry of health is>3. Kazantseva, N. Century, Timofeev Century. So, Nifontov receives information L. D., et al. Hyperbaric oxygenation at low differential pressures in the treatment of multiple sclerosis.// The materials of the Interregional scientific-practical conference on infectious diseases of the nervous system. Kostroma, 1990, S. 156-159.

4. L. A. Isaeva, S. N. Epuni, G. A. Laskina, ,And. Luskin. The method of treatment of periarteritis nodosa. N 965425, 15.10.1982, bull.N 38.

5. Chernyshev, A. a Method for the treatment of allergic dermatitis. The invention N 1303159, 15.04.87, bull. N 14.

6. Pakhomov Century. And., Erin C. A. and other treatment of acute leukemia in children. The invention N 1341761, 15.11.89, bull. N 42. 7.

7. Pozdnyakov A. N., Stepanova T. C. treatment of leukopenia with acute lymphoblastic leukemia in children. The invention N 2063737, 20.07.1996, bull. N 20.

8. Pakhomov C. I., Sokolov, A. E., Karam, E. K., the Method of increasing the resistance of cells to pathogenic effects of human immunodeficiency virus and suppression of its reproduction. The Invention N 2084212, 24.10.1997.

1. Method for the treatment and prevention of multiple sclerosis and degenerations of the nervous system, including the overall impact of excessive barometric pressure in treatment chamber, characterized in that it further administered drugs, F for 1 2 weeks at a pressure in the pressure chamber in the range of 1.03 to 1.1 ATA for 10 to 20 minutes, with individual selection of the parameters of treatment and number of sessions carried out depending on the severity and nature of the disease, controlling regression of neurological symptoms and increase of tissue respiration by capnography and/or AAS before and after each session, conduct refresher courses at least 2 times per year, under the control of the patient, lipid peroxidation, immune status, evoked potentials, EEG and magnetic resonance imaging.

2. The method according to p. 1, characterized in that the quality of drugs that enhance mitochondrial oxidation, can be used ubiquinone, bioflavnoidy (Pycnogenol®) or succinic acid.

 

Same patents:

Antihypoxic tool // 2098085
The invention relates to medicine, specifically to the creation of medicines, stamina body tissues to hypoxia by preventing disturbances of the homeostasis of energy systems and restoration in pathology, ischemic and hypoxic cell damage

The invention relates to the production of Riboflavin (vitamin B2)

The invention relates to medicine, particularly cardiology

The invention relates to medicine and relates to a tool for the treatment of stomatitis

The invention relates to wound-healing and anti-inflammatory agent and can be used for the treatment of wounds, ulcers and burns of the mucous membranes and skin

The invention relates to the technology of known derivatives hinolincarbonova acid, in particular to a method for producing derivatives of 3-hinolincarbonova acid

The invention relates to medicine, namely to the chemical-pharmaceutical industry and relates to aqueous concentrated solution of argatroban

The invention relates to new heterocyclic compounds of the formula I where ring a and ring To represent optionally substituted benzene or cycloalkane ring or optionally substituted 5 - or 6-membered aromatic heterocyclic ring containing one to two heteroatoms selected from nitrogen, sulfur and oxygen

The invention relates to the use of derivatives of 2-amino-4-phenyl-4-oxomalonate acid for the prevention or treatment neuropteroidea diseases, such as Huntington's chorea, Alzheimer's disease and Parkinson's disease, dementia caused by acquired immunodeficiency syndrome (AIDS) or infarction, cerebral ischemia, cerebral hypoxia or epilepsy

The invention relates to medicine and can be used to prevent or reduce the intensity of side effects and complications of dialysis used to treat patients with renal insufficiency
Up!